Cash Flow Statement

Amortization of Deferred Charges Amortization of Deferred Charges Amortization of Goodwill Amortization of Goodwill Asset Writedowns and Impairment Asset Writedowns and Impairment Beginning Cash Balance Beginning Cash Balance Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Intangibles Change in Intangibles Change in Receivables Change in Receivables Change in Taxes Change in Taxes Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Preferred Shares Issued Share-based Compensation Share-based Compensation Shares Issued Shares Repurchased

Daily Values

Growth Metrics

OptimizeRx (OPRX) Gains from Sales and Divestitures (2023 - 2024)

OptimizeRx's Gains from Sales and Divestitures history spans 2 years, with the latest figure at $295018.0 for Q4 2024.

On a quarterly basis, Gains from Sales and Divestitures rose 107.97% to $295018.0 in Q4 2024 year-over-year; TTM through Dec 2024 was $295018.0, a 107.97% increase, with the full-year FY2024 number at $295018.0, up 107.97% from a year prior.
Gains from Sales and Divestitures hit $295018.0 in Q4 2024 for OptimizeRx, up from $141859.0 in the prior quarter.
Over the last five years, Gains from Sales and Divestitures for OPRX hit a ceiling of $295018.0 in Q4 2024 and a floor of $141859.0 in Q4 2023.